(CercleFinance.com) – Euroapi announces that it has expanded its collaboration with Sanofi entering into their framework development agreement dated October 1, 2021, in order to support Sanofi’s mRNA vaccine platform through the development of lipid nanoparticles.
In this context, the active ingredient solutions company will develop and optimize innovative chemical synthesis routes and will produce GMP (good manufacturing practices) batches of several second-generation cationic lipids.
Euroapi will focus on lipids that are currently being tested for Phase I/II clinical trials, and which will support Sanofi’s mRNA vaccine platform, targeting indications such as influenza.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
